CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

Simone WeberVictoria KehlJohanna ErberKarolin I WagnerAna-Marija JetzlspergerTeresa BurrellKilian SchoberPhilipp SchommersMax AugustinClaudia S CrowellMarkus GerhardChristof WinterAndreas MoosmannChristoph D SpinnerUlrike ProtzerDieter HoffmannElvira D'IppolitoDirk H Busch

Published in: PloS one (2022)

We identified 'CMV-seropositivity' as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
respiratory syndrome coronavirus
newly diagnosed
chronic kidney disease
prognostic factors
human health
copy number
gene expression
patient reported outcomes
dna methylation
drug induced